Catalyst's New Drug Was Old News, Investors Say

Law360, New York (October 28, 2013, 2:07 PM EDT) -- A putative class of Catalyst Pharmaceutical Partners Inc. investors on Thursday accused the company in Florida federal court of inflating its stock price by misrepresenting its orphan drug Firdapse as new, when another company had been giving it away for decades.

Lead plaintiff Atul Kamar Sood accuses the drug company, which develops prescription drugs for rare neuromuscular and neurological diseases, of touting the development of the drug Firdapse — used to treat Lambert-Eaton myasthenic syndrome, an autoimmune disorder — while failing to mention that New Jersey-based...
To view the full article, register now.




Case Information

Case Title

Sood v. Catalyst Pharmaceutical Partners Inc. et al

Case Number



Florida Southern

Nature of Suit



Ursula Ungaro

Date Filed

October 25, 2013


Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.